MA43270A - Inhibiteur de la c1 estérase humaine recombinante et ses utilisations - Google Patents

Inhibiteur de la c1 estérase humaine recombinante et ses utilisations

Info

Publication number
MA43270A
MA43270A MA043270A MA43270A MA43270A MA 43270 A MA43270 A MA 43270A MA 043270 A MA043270 A MA 043270A MA 43270 A MA43270 A MA 43270A MA 43270 A MA43270 A MA 43270A
Authority
MA
Morocco
Prior art keywords
inhibitor
recombinant human
human esterase
esterase
recombinant
Prior art date
Application number
MA043270A
Other languages
English (en)
Inventor
Germano Coppola
Angela W Norton
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA43270A publication Critical patent/MA43270A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
MA043270A 2015-11-19 2016-11-18 Inhibiteur de la c1 estérase humaine recombinante et ses utilisations MA43270A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562257711P 2015-11-19 2015-11-19

Publications (1)

Publication Number Publication Date
MA43270A true MA43270A (fr) 2021-06-02

Family

ID=57543175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043270A MA43270A (fr) 2015-11-19 2016-11-18 Inhibiteur de la c1 estérase humaine recombinante et ses utilisations

Country Status (9)

Country Link
US (1) US20180334493A1 (fr)
EP (1) EP3377093B1 (fr)
JP (3) JP7189767B2 (fr)
CN (1) CN108463243B (fr)
BR (1) BR112018010160A8 (fr)
CA (1) CA3005906A1 (fr)
ES (1) ES2927271T3 (fr)
MA (1) MA43270A (fr)
WO (1) WO2017087882A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019166572A1 (fr) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Système pharmaceutique pour l'administration transdermique d'un inhibiteur de la c1 estérase
CA3109924A1 (fr) 2018-08-24 2020-02-27 Csl Behring Gene Therapy, Inc. Production de vecteur dans un milieu sans serum
JP2022505307A (ja) * 2018-10-17 2022-01-14 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１－ｉｎｈを精製する方法
SE1930321A1 (en) * 2019-10-08 2021-04-09 Veronique Chotteau A method to feed component in perfusion culture
CN115176022A (zh) * 2019-10-23 2022-10-11 夏尔人类遗传性治疗公司 用于遗传性血管性水肿的基于腺相关病毒载体的基因疗法
CN111087475B (zh) * 2019-12-25 2022-07-08 东莞市东阳光生物药研发有限公司 Fgf21融合蛋白及抑制其降解的方法
RU2769201C2 (ru) * 2020-06-23 2022-03-29 Акционерное общество "ГЕНЕРИУМ" Способ получения высокоочищенного рекомбинантного ингибитора с1-эстеразы человека для медицинского применения
KR20230045615A (ko) * 2020-08-14 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 단백질을 제조하는 방법

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5622930A (en) * 1989-10-27 1997-04-22 Clb C1 inhibitor muteins and uses thereof
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
FR2672895B1 (fr) 1991-02-15 1995-05-12 Transgene Sa Procede de purification d'une proteine fortement glycosylee.
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP3543106B2 (ja) * 1999-07-21 2004-07-14 大阪大学長 膜結合型ｃ１インアクチベーター
JP2003521914A (ja) * 2000-01-31 2003-07-22 ファーミング インテレクチュアル プロパティー ベー．フェー． トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター
ATE359358T1 (de) 2002-07-15 2007-05-15 Immunex Corp Verfahren und medien zur kontrolle der sialysierung von proteinen, die von säugetierzellen produziert werden
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7384754B2 (en) 2003-10-31 2008-06-10 Agilent Technologies, Inc. Enrichment and tagging of glycosylated proteins
GB0507123D0 (en) 2005-04-08 2005-05-11 Isis Innovation Method
EP3026109B1 (fr) 2005-12-08 2022-03-09 Amgen Inc. Production amelioree de glycoproteines utilisant le manganese
PL1965831T3 (pl) * 2005-12-21 2011-12-30 Pharming Intellectual Property B V Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego
EP2623610B1 (fr) 2006-02-10 2015-04-29 Life Technologies Corporation Marquage et détection de protéines modifiées post-traductionnellement
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
JP2011500032A (ja) 2007-10-12 2011-01-06 シグマ−アルドリッチ・カンパニー 糖タンパク質のシアリル化を改善するための組成物および方法
JP5781308B2 (ja) 2008-02-19 2015-09-16 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 異種タンパク質を得る方法およびインスリン類似体
WO2009143493A2 (fr) * 2008-05-22 2009-11-26 Attagene Inc. Modulateurs des voies de signalisation dépendantes de tnfa et leurs utilisations
EP2166085A1 (fr) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Cellules modifiées bivalentes
CA2752175A1 (fr) 2009-02-26 2010-09-02 Battelle Energy Alliance, Llc Alteration et modulation de l'activite proteique en faisant varier la modification post-traductionnelle alteration and modulation of protein activity by varying post-translational modification
WO2011116291A1 (fr) * 2010-03-18 2011-09-22 Thrombolytic Science International Production d'un inhibiteur du c1 humain dans des cellules humaines
CN103458983A (zh) 2011-02-10 2013-12-18 莱顿大学医学中心 通过使用含棉的固定相的色谱法纯化聚糖和/或糖缀合物的方法
CA2840951A1 (fr) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Procede de purification d'une proteine de fusion fc
AU2012340501A1 (en) 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6127063B2 (ja) * 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
WO2013138694A1 (fr) * 2012-03-16 2013-09-19 Enzon Pharmaceuticals, Inc. Conjugués polymères d'inhibiteurs de la c1-estérase
EP2964255B1 (fr) * 2013-03-08 2020-11-04 CSL Behring GmbH Traitement et prévention d'une lésion d'ischémie-reperfusion à distance
EP2968434B1 (fr) * 2013-03-15 2017-06-28 Shire Viropharma Incorporated Compositions de c1-inh pour utilisation dans la prévention et le traitement de l' angio-oedème héréditaire (aoh)
CN106255532A (zh) * 2014-02-28 2016-12-21 桑塔鲁斯公司 用c1抑制剂治疗遗传性血管性水肿
JP6591437B2 (ja) * 2014-03-20 2019-10-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (fr) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Inhibiteur recombinant de la c1-estérase et utilisation de celui-ci
EP3042952A1 (fr) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH Glycoprotéines recombinantes sialylées o-glycanes et lignées cellulaires de production de celles-ci

Also Published As

Publication number Publication date
BR112018010160A2 (pt) 2018-11-21
BR112018010160A8 (pt) 2019-02-26
JP7189767B2 (ja) 2022-12-14
US20180334493A1 (en) 2018-11-22
JP2018538270A (ja) 2018-12-27
CN108463243B (zh) 2022-06-14
CN108463243A (zh) 2018-08-28
JP2021155438A (ja) 2021-10-07
EP3377093B1 (fr) 2022-07-13
ES2927271T3 (es) 2022-11-03
CA3005906A1 (fr) 2017-05-26
JP2023083499A (ja) 2023-06-15
EP3377093A1 (fr) 2018-09-26
WO2017087882A1 (fr) 2017-05-26

Similar Documents

Publication Publication Date Title
MA43270A (fr) Inhibiteur de la c1 estérase humaine recombinante et ses utilisations
KR20180084895A (ko) 효소 내재화 조성물 및 방법
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
MA43552A (fr) Protéines immunomodulatrices à variants de cd80 et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA50502A (fr) Adénovirus et utilisations associées
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA54328A (fr) Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
BR112017002511A2 (pt) sistemas e métodos de almofada terapêutica
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA46700A (fr) Variants polypeptidiques et ses utilisations
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
MA43567A (fr) Anticorps pacap et leurs utilisations
BR112015023207A8 (pt) composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
MA53991A (fr) Protéines de fusion de l'inhibiteur de la c1 estérase et leurs utilisations
MA47449A (fr) Variants polypeptidiques et ses utilisations
IL256671A (en) System and method of assessing endothelial function
MA43052A (fr) Inhibiteurs de la kallicréine plasmatique humaine
FI20155621A (fi) Menetelmä ja tuote
MA44968A (fr) Esters d'oxaborole et leurs utilisations
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
MA49905A (fr) Polyesteramines et polyesterquats
KR20180085008A (ko) 항-pcsk9 항체 및 그의 용도